Bank of New York Mellon’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $160M | Sell |
294,413
-34,735
| -11% | -$19.6M | 0.03% | 484 |
|
|
2026
Q1 | $195M | Sell |
329,148
-4,481
| -1% | -$2.23M | 0.04% | 393 |
|
|
2025
Q4 | $163M | Sell |
333,629
-17,826
| -5% | -$8.3M | 0.03% | 439 |
|
|
2025
Q3 | $147M | Sell |
351,455
-11,016
| -3% | -$3.7M | 0.03% | 476 |
|
|
2025
Q2 | $104M | Sell |
362,471
-37,736
| -9% | -$11.3M | 0.02% | 618 |
|
|
2025
Q1 | $123M | Buy |
400,207
+783
| +0.2% | +$268K | 0.02% | 531 |
|
|
2024
Q4 | $141M | Sell |
399,424
-1,693
| -0.4% | -$622K | 0.03% | 493 |
|
|
2024
Q3 | $144M | Sell |
401,117
-33,722
| -8% | -$11.4M | 0.03% | 488 |
|
|
2024
Q2 | $139M | Sell |
434,839
-23,494
| -5% | -$6.22M | 0.03% | 498 |
|
|
2024
Q1 | $105M | Sell |
458,333
-95,535
| -17% | -$21.6M | 0.02% | 630 |
|
|
2023
Q4 | $122M | Sell |
553,868
-17,200
| -3% | -$3.96M | 0.02% | 561 |
|
|
2023
Q3 | $129M | Sell |
571,068
-25,162
| -4% | -$5.8M | 0.03% | 510 |
|
|
2023
Q2 | $132M | Sell |
596,230
-13,923
| -2% | -$3.08M | 0.03% | 516 |
|
|
2023
Q1 | $137M | Buy |
610,153
+31,546
| +5% | +$7.78M | 0.03% | 486 |
|
|
2022
Q4 | $161M | Sell |
578,607
-27,925
| -5% | -$7.05M | 0.04% | 421 |
|
|
2022
Q3 | $127M | Sell |
606,532
-174,377
| -22% | -$39M | 0.03% | 494 |
|
|
2022
Q2 | $184M | Sell |
780,909
-51,342
| -6% | -$10.4M | 0.04% | 386 |
|
|
2022
Q1 | $149M | Sell |
832,251
-181,714
| -18% | -$34.6M | 0.03% | 508 |
|
|
2021
Q4 | $219M | Buy |
1,013,965
+169,007
| +20% | +$33.2M | 0.04% | 402 |
|
|
2021
Q3 | $156M | Buy |
844,958
+123,295
| +17% | +$24.3M | 0.03% | 491 |
|
|
2021
Q2 | $129M | Buy |
721,663
+53,760
| +8% | +$10.2M | 0.03% | 582 |
|
|
2021
Q1 | $112M | Buy |
667,903
+165,383
| +33% | +$27.6M | 0.02% | 649 |
|
|
2020
Q4 | $76.3M | Buy |
502,520
+17,440
| +4% | +$2.29M | 0.02% | 783 |
|
|
2020
Q3 | $49M | Sell |
485,080
-4,169
| -0.9% | -$457K | 0.01% | 934 |
|
|
2020
Q2 | $59.2M | Buy |
489,249
+18,893
| +4% | +$2.13M | 0.02% | 791 |
|
|
2020
Q1 | $44.6M | Sell |
470,356
-3,559
| -0.8% | -$338K | 0.01% | 820 |
|
|
2019
Q4 | $41.7M | Sell |
473,915
-54,128
| -10% | -$4.76M | 0.01% | 1086 |
|
|
2019
Q3 | $42.1M | Sell |
528,043
-29,488
| -5% | -$2.37M | 0.01% | 1051 |
|
|
2019
Q2 | $43.5M | Sell |
557,531
-61,458
| -10% | -$5.75M | 0.01% | 1058 |
|
|
2019
Q1 | $72.6M | Buy |
618,989
+48,129
| +8% | +$5.61M | 0.02% | 745 |
|
|
2018
Q4 | $62.2M | Sell |
570,860
-48,874
| -8% | -$5.67M | 0.02% | 765 |
|
|
2018
Q3 | $79.3M | Sell |
619,734
-48,925
| -7% | -$6.05M | 0.02% | 738 |
|
|
2018
Q2 | $75.7M | Sell |
668,659
-39,680
| -6% | -$4.36M | 0.02% | 748 |
|
|
2018
Q1 | $79.6M | Sell |
708,339
-62,564
| -8% | -$7.95M | 0.02% | 724 |
|
|
2017
Q4 | $114M | Sell |
770,903
-7,550
| -1% | -$960K | 0.03% | 568 |
|
|
2017
Q3 | $91.2M | Sell |
778,453
-22,420
| -3% | -$2.86M | 0.03% | 653 |
|
|
2017
Q2 | $104M | Sell |
800,873
-29,682
| -4% | -$3.7M | 0.03% | 564 |
|
|
2017
Q1 | $112M | Buy |
830,555
+55,649
| +7% | +$8.43M | 0.03% | 529 |
|
|
2016
Q4 | $111M | Buy |
774,906
+39,680
| +5% | +$5.07M | 0.03% | 523 |
|
|
2016
Q3 | $86.8M | Buy |
735,226
+93,872
| +15% | +$11.3M | 0.03% | 601 |
|
|
2016
Q2 | $67.9M | Sell |
641,354
-56,976
| -8% | -$6.36M | 0.02% | 703 |
|
|
2016
Q1 | $77.8M | Buy |
698,330
+31,386
| +5% | +$3.97M | 0.02% | 656 |
|
|
2015
Q4 | $104M | Buy |
666,944
+34,062
| +5% | +$4.96M | 0.03% | 512 |
|
|
2015
Q3 | $83.1M | Sell |
632,882
-11,395
| -2% | -$1.83M | 0.03% | 611 |
|
|
2015
Q2 | $112M | Buy |
644,277
+47,135
| +8% | +$8.48M | 0.03% | 536 |
|
|
2015
Q1 | $103M | Buy |
597,142
+61,885
| +12% | +$9.43M | 0.03% | 592 |
|
|
2014
Q4 | $69.3M | Sell |
535,257
-86,710
| -14% | -$11.2M | 0.02% | 735 |
|
|
2014
Q3 | $80M | Sell |
621,967
-275,774
| -31% | -$28.4M | 0.02% | 656 |
|
|
2014
Q2 | $79.4M | Sell |
897,741
-19,726
| -2% | -$1.9M | 0.02% | 677 |
|
|
2014
Q1 | $86.3M | Buy |
917,467
+1,019
| +0.1% | +$104K | 0.02% | 630 |
|
|
2013
Q4 | $104M | Sell |
916,448
-28,903
| -3% | -$2.61M | 0.03% | 562 |
|
|
2013
Q3 | $74.5M | Buy |
945,351
+53,568
| +6% | +$3.92M | 0.02% | 666 |
|
|
2013
Q2 | $58.7M | Buy |
+891,783
| New | +$57.4M | 0.02% | 736 |
|
Other funds holding UTHR
Bank of New York Mellon's UTHR Position: Q2 2026 in Review
Bank of New York Mellon reduced its United Therapeutics (UTHR) stake by 11% in Q2 2026, selling an estimated $19.6M and leaving 294,413 shares worth $160M. The position accounts for 0.03% of the portfolio, ranked #484.
Bank of New York Mellon first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $219M in Q4 2021. 505 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Bank of New York Mellon held 294,413 shares of United Therapeutics worth $160M as of Q2 2026.
- Bank of New York Mellon sold 34,735 United Therapeutics shares in Q2 2026, an estimated $19.6M.
- United Therapeutics made up 0.03% of Bank of New York Mellon's portfolio in Q2 2026, its #484 holding.
- Bank of New York Mellon first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's United Therapeutics position peaked at $219M in Q4 2021.
- 505 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.